Berzosertib

Generic Name: Berzosertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₅N_₅O_₃S

CAS Number: 1232416-25-9

Unique Ingredient Identifier: L423PRV3V3

Background: Berzosertib (VX-970) has been used in trials studying the treatment of Ovarian Neoplasms, Ovarian Serous Tumor, Adult Solid Neoplasm, Advanced Solid Tumor, and Advanced Solid Neoplasm, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

New drug combination shows promise for small cell lung cancer

New research from Icahn School of Medicine at Mount Sinai shows promise in treating small cell lung cancer (SCLC) by inhibiting ATR protein, enhancing immune response via cGAS-STING pathway, and combining ATR inhibitors with anti-PD-L1 antibodies. A clinical trial is planned for 2025.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy